Jump to Navigation


The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.


Recent News
Nov 18, 2016

In the midst of a devastating global crisis 2 years ago, a Ugandan physician was infected with Ebola in Sierra Leone as he was treating patients. He was hospitalized at the Frankfurt University...

Nov 10, 2016

Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal second quarter year ended...

View all News Releases

Thursday, November 10, 2016
4:30pm EST
Tuesday, October 18, 2016
3:30pm PDT

View All Events

print email

Back to Top

Site 'Subpage' Navigation:

Investor Relations

Investor Contact

Aethlon Medical, Inc.

Back to Top